

**PROPOSED RESOLUTIONS ON THE DIFFERENT ITEMS ON THE AGENDA OF
THE ORDINARY AND EXTRAORDINARY GENERAL SHAREHOLDERS'
MEETING OF
"LABORATORIO REIG JOFRE, S.A." OF 29 APRIL 2021**

FIRST Financial Statements and corporate management:

- 1.1. **Review and approval, as the case may be, of the Company's Individual Financial Statements corresponding to the financial year 2020, duly reviewed by the Company's auditors.**
 - 1.2 **Review and approval, as the case may be, of the Company's Individual Management Report corresponding to the financial year 2020, duly reviewed by the Company's auditors.**
 - 1.3. **Review and approval, as the case may be, of the Company and its subsidiaries' Consolidated Financial Statements corresponding to the financial year 2020, duly reviewed by the Company's auditors.**
 - 1.4. **Review and approval, as the case may be, of the Company and its subsidiaries' Consolidated Management Report for the financial year 2020, duly reviewed by the Company's auditors.**
 - 1.5. **Review and approval, as the case may be, of the Consolidated Statement of Non-Financial Information for the financial year 2020.**
 - 1.6. **Approval, if applicable, of the proposal for the application of the results corresponding to the financial year 2020.**
 - 1.7. **Approval, if applicable, of the social management carried out during the financial year 2020.**
- 1.1. To approve the Company's Individual Financial Statements (comprising the Balance Sheet, the Profit and Loss Account, the Statement of Changes in Equity, the Statement of Cash Flow and the Annual Report) for the year ended 31 December 2020, prepared by the Board of Directors on 25 February 2021.
 - 1.2. To approve the Company's Individual Management Report for the year ended 31 December 2020.
 - 1.3. To approve the Company and its subsidiaries' Consolidated Financial Statements (comprising the Consolidated Statements of Financial Position, the Consolidated Income Statements, the Consolidated Statements of Comprehensive Income, the Consolidated Statements of Changes in Equity, the Consolidated Statements of Cash Flow and the Consolidated Annual Report) for the year ended 31 December 2020, prepared by the Board of Directors on 25 February 2021.
 - 1.4. To approve the Company and its subsidiaries' Consolidated Directors' Report for the year ended 31 December 2020.

The Company's Auditors have issued the mandatory audit reports, from which it is concluded that the Financial Statements and the Individual and Consolidated Management Reports, prepared by the Board of Directors on 25 February 2021,

comply with the requirements of Article 269 of the Capital Companies Act and other applicable regulations.

- 1.5. To approve the Company's Consolidated Statement of Non-Financial Information for the year ended 31 December 2020, which is contained in the consolidated directors' report.
- 1.6. To approve the distribution of the Company's profit for the year ended 31 December 2020, as follows:

<u>Basis for distribution</u>	
Profit for the year	€ 1,930,822.57
<u>Distribution</u>	
Other reserves (voluntary)	€ 1,930,822.57
	<u>€ 1,930,822.57</u>

- 1.7. To approve the management of the Board of Directors for the year ended 31 December 2020.

SECOND Submission to vote, in a consultative capacity, of the Annual Report on the Remuneration of the Directors of the Company corresponding to the financial year 2020.

To approve, on a consultative basis, the Annual Report on the Remuneration of the members of the Company's Board of Directors, prepared and approved by the Board of Directors on 25 February 2021, subsequent to a favourable report from the Appointments and Remuneration Committee, under the provisions of Article 541 of the Capital Companies Act, and in accordance with the model approved by Announcement 4/2013, of June 12, of the National Securities Market Commission (CNMV), as amended by Announcement 7/2015 of December 22, sent to the CNMV and which has been made available to the shareholders since the publication of the announcement of the call for the General Shareholders' Meeting.

THIRD Approval, if applicable, of the Company Directors' Remuneration Policy.

Pursuant to the provisions of Article 529 (19) of the Capital Companies Act, to approve the Company Directors' Remuneration Policy justified in the explanatory report thereof prepared by the Appointments and Remuneration Committee on 18 March 2021 with both documents validated on the same date by the Board of Directors, which also agreed to submit them to the General Shareholders' Meeting for its eventual approval.

Both documents were made available to the Shareholders from the publication of the General Shareholders' Meeting notice.

FOURTH Adoption, when applicable and within the "Reig Jofre Flexible Dividend"

plan, of i) the distribution of dividends against reserves and, ii) of an increase in the Company's share capital with a charge to reserves

for an amount determined in accordance with the terms of the agreement,

through the issuance of new ordinary shares with a nominal value of fifty (50)

cents and with provision for incomplete allocation. Offer to shareholders for the purchase of their free allocation rights for a guaranteed price. Application for admission to trading of the shares issued. Delegation of powers to the Board of Directors, with express power of substitution, including, among other matters, the power to redraft the article of the Company Bylaws regulating share capital.

1. Distribution of dividends charged to reserves.

Approval of the distribution of a dividend charged against unrestricted reserves for a maximum amount of €3,532,904.83.

2. Capital increase with charge to reserves.

To increase the share capital by the amount resulting from multiplying: (a) the nominal value of each share of "LABORATORIO REIG JOFRE, S.A." (hereinafter, the "Company"), equivalent to fifty (50) Euro cents, by (b) the total determinable number of new shares in the Company that are issued, in accordance with the formula indicated in section 3 below, on the date of execution of the Capital Increase (all new shares in the Company issued through the execution of this Agreement shall be jointly referred to as the "New Shares," and each individually as a "New Share"). Under no circumstances may the amount exceed the maximum limit of €3,532,904.83 (hereinafter, the "**Capital Increase**").

The Capital Increase is to be implemented through the issue and emission, where applicable, on the date of execution of the Capital Increase, of the New Shares, which will be ordinary shares with a par value of fifty (50) cents (Euro) each, of the same class and series as the outstanding shares, represented by book entries.

The Capital Increase will be charged in full against the reserves provided for in Article 303.1 of the Corporate Enterprises Act. When executing the Capital Increase, the Board of Directors, with express power of substitution, will determine the reserve(s) to be employed and the amount of the same, in accordance with the balance that serves as the basis for the operation.

The New Shares will be issued at par, i.e., at their nominal value of fifty (50) cents (Euro) each, without a share premium, and will be allocated free of charge to the Company's shareholders.

The Capital Increase may be executed, within one year as of the date of adoption of this agreement, by the Board of Directors, with express power of substitution, at its sole discretion and without the requirement, therefore, to report to the General Shareholders' Meeting and, in accordance with the legal and financial conditions at the time of execution of the Capital Increase, to offer the Company's shareholders a flexible and efficient remuneration formula. The number of New Shares to be issued shall be the number resulting from the formula indicated in section 3 below, and the Option Amount (as defined in section 3 below) shall be equivalent to the maximum amount of € 3,042,498.28. 3.

Article 311 of the Corporate Companies Act contemplates the possibility of an incomplete allocation of the Capital Increase in the event that the Company, a shareholder or a third-party holder of free allocation rights renounce all or part of their pre-emptive rights at the time of the execution of the Capital Increase. In the event that such a waiver occurs, the share capital will be increased by the corresponding amount.

3. New Shares to be issued.

The number of New Shares to be issued will be the result of the application of the following formula, rounding down the result to the next whole number:

$\text{NAN} = \text{NTAcc} / \text{No. of Rights}$
--

Where:

NAN = Number of New Shares to be issued;

NTAcc = Number of outstanding Company shares on the date on which the Board of Directors, or the body which it delegates, agrees to carry out the Capital Increase; and

No. rights = Number of pre-emptive subscription rights necessary for the allocation of a New Share, which will be the result of the application of the following formula, rounding up the result to the next whole number:

No. of rights = NTAcc / Provisional no. of shares, where,

Provisional no. of shares = Amount of Option / PreQuot.

For these purposes, the "Amount of Option" shall be understood to be the maximum value of €3,532,904.83, set by the Board of Directors.

"PreQuot" shall be the mathematical mean of the weighted average prices of the Company's shares on the Bilbao, Madrid, Barcelona and Valencia Stock Exchanges in the five trading sessions prior to the Board of Directors' agreement (or the agreement of the body which the Board delegates) determining the number of pre-emptive subscription rights necessary for

the allocation of a New Share, as well as the Purchase Price (as defined below) rounded to the nearest thousandth of Euro.

4. Pre-emptive subscription rights.

Each outstanding Company share will grant a pre-emptive subscription right.

The number of pre-emptive subscription rights required to receive a New Share will be automatically determined in accordance with the ratio of outstanding Company shares on the date of execution of the Capital Increase (NTAcc) against the provisional number of New Shares, calculated according to the formula set out in section 3 above. Specifically, holders of pre-emptive subscription rights will be entitled to receive one New Share for each number of pre-emptive subscription rights determined in accordance with the provisions of section 3 above (No. rights) held by them.

If the number of pre-emptive subscription rights required for the allocation of a New Share (No. rights) multiplied by the number of New Shares to be issued (NAN) results in a number that is lower than the number of outstanding Company shares on the date of execution of the Capital Increase (NTAcc), the Company will waive a number of pre-emptive subscription rights equal to the difference between the two figures, for the sole purpose of having a whole number of New Shares and not a fraction.

Pre-emptive subscription rights will be assigned to those who are legitimated in the accounting records of Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A. Unipersonal (IBERCLEAR) on the corresponding date.

Pre-emptive subscription rights shall be transferable under the same conditions as the shares from which they derive. Pre-emptive subscription rights may be traded on the market during the period determined by the Board of Directors, with express power of substitution for a period of at least fifteen calendar days. During the aforementioned period, sufficient pre-emptive subscription rights may be acquired in the market and in the proportion necessary to receive New Shares.

5. Irrevocable commitment to purchase the pre-emptive subscription rights.

In conjunction with the execution of the Capital Increase, the Company will assume, under the conditions indicated below, an irrevocable commitment to purchase the free allocation rights at the price indicated below (hereinafter, the "**Purchase Commitment**"). The Purchase Commitment shall be in force and may be accepted during the term, within the period of negotiation of the rights, determined by the Board of Directors, with express power of substitution. To this effect, it is agreed to authorise the Company to acquire such free allocation rights, with the maximum limit of the total rights that are issued, with obligatory compliance with the legal limitations.

The purpose of the Purchase Commitment assumed by the Company will be applicable to the free allocation rights received by those who are legitimated in the accounting records of Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores,

S.A. Unipersonal (IBERCLEAR) on the corresponding date, excluding those rights that have been transmitted on the market.

The "Purchase Price" will be the fixed price at which the Company acquires each free allocation right under the Purchase Commitment, and will be calculated in accordance with the following formula, rounded up to the nearest thousandth of a Euro and, in case of one-half of a thousandth of a Euro, to the next thousandth of a Euro:

$\text{Purchase Price} = \text{PreCot} / (\text{No. rights} + 1)$

The acquisition by the Company of the free allocation rights as a consequence of the Purchase Commitment will be charged against the reserves provided for in Article 303.1 of the Corporate Enterprises Act.

6. Balance for the operation and reserve charged against the Capital Increase.

The balance that serves as a basis for the operation is that corresponding to the year ended December 31, 2019, duly audited by the Company's auditors, that is, KPMG Auditores, S.L., and submitted to the approval of this General Shareholders' Meeting.

The Capital Increase will be charged in full against the reserves provided for in Article 303.1 of the Corporate Enterprises Act. When executing the Capital Increase, the Board of Directors, with express power of substitution, will determine the reserves to be employed and the amount of the same, in accordance with the balance that serves as the basis for the operation.

7. Representation of New Shares.

The New Shares will be represented by book entries, the accounting registration of which is the responsibility of Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A. Unipersonal (IBERCLEAR) and its participating entities.

8. New Shares Rights.

The New Shares will confer upon their holders the same political and economic rights as the Company's outstanding ordinary shares, as of the date on which the Capital Increase is declared subscribed and paid-in.

9. Blocked shares

Following the negotiation period for the free allocation rights, New Shares that have not been allocated for reasons not attributable to the Company will be blocked and held at the disposal of those able to demonstrate the legitimate ownership of the corresponding free allocation rights. Three years as of the termination date of the aforementioned free allocation rights trading period, New Shares that are still pending allocation may be sold in accordance with the provisions of Article 117.3 of the Corporate Enterprises Act, at the risk and expense of the interested parties. The cash amount of the aforementioned sale will be deposited with the Bank of Spain or in the General Deposit Fund at the disposal of the interested parties.

10. Request for admission to trading.

To request admission to trading of the New Shares issued pursuant to this Capital Increase agreement on the Stock Exchanges of Bilbao, Madrid, Barcelona and Valencia, via the Spanish Stock Market Interconnection System (Continuous Market), as well as implementing the processes and actions necessary and presenting the documents required before the competent organisations for the admission to trading of the New Shares issued as a result of the agreed Capital Increase, with express mention of the Company's submission to the existing and future regulations relative to the stock markets and, specifically, relative to contracting, permanence and exclusion from official trading.

It is expressly stated that, in the event of a subsequent request for the exclusion from trading of the Company's shares, such a measure will be adopted with the applicable formalities and, in such a case, the interests of shareholders who oppose or who do not vote in favour of the exclusion agreement will be guaranteed, in compliance with the requirements of the Corporate Enterprises Act and related provisions, and in accordance with the provisions of Legislative Degree 4/2015, of October 23, which grants approval to the redrafted text of the Securities Market Act, and the implementing provisions in force at all times.

11. Execution of the Capital Increase.

Within one year as of the date of this agreement, the Board of Directors, with express power of substitution, may indicate the date on which the Capital Increase agreement is to be executed and establish its conditions in all matters that are not covered in this agreement. Notwithstanding the above, if the Board of Directors, with express power of substitution, does not consider it convenient to execute all or part of the Capital Increase within the aforementioned period, it may abstain from the same. In such case, it must inform the next General Shareholders' Meeting of its decision.

Specifically, the Board of Directors will analyse and take into account the market conditions, those of the Company or those arising from any fact or event with social or economic significance and, in the event that these or any other elements representing sufficient reason, in the opinion of the Board, for not executing the Capital Increase, the Board may refrain from doing so. Similarly, the Capital Increase will be rendered without effect or value if, within the term of one year established by the General Shareholders' Meeting for its execution, the Board of Directors does not exercise the powers delegated.

Upon the conclusion of the trading period for the free allocation rights, the following shall apply:

- a) The New Shares will be assigned to those who, in accordance with the accounting records of Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A. Unipersonal (IBERCLEAR) and its participating entities, are entitled to free allocation rights in the proportion as determined in section 4 above.

b) The trading period for the free allocation rights will be declared closed and the formalisation for accounting purposes of the allocation of the accounts against which the Capital Increase is to be charged, in the corresponding amount, with the payment being made with said allocation.

Similarly, once the trading period for the pre-emptive subscription rights has concluded, the Board of Directors, with express power of substitution, will adopt the corresponding agreements to amend the By-Laws in order to reflect the new share capital and the number of shares resulting from the execution of the Capital Increase and the application for admission to trading of the New Shares on the Bilbao, Madrid, Barcelona and Valencia Stock Exchanges, through the Spanish Stock Market Interconnection System (Continuous Market).

12. Delegation for the execution of the Capital Increase.

Delegate to the Board of Directors, in accordance with the provisions of Article 297.1.a) of the Corporate Enterprises Act, with express power of substitution, the power to indicate the date on which the Capital Increase agreement is to be executed and, when applicable, establish its conditions in all matters that are not covered in this agreement. Specifically, and solely for the purposes of illustration, the following powers are among those delegated to the Board of Directors, with express power of substitution:

1. Indicate the date on which the Capital Increase must be executed, in all cases within one year as of its approval by the General Shareholders' Meeting, and determine the execution schedule of the same.
2. Establish the exact amount of the Capital Increase, the number of New Shares and the number of free allocation rights necessary for the allocation of a New Share, applying the rules established in this agreement.
3. Determine the reserve(s), from those contemplated in this agreement, charged against those executed in relation to the Capital Increase and the acquisition by the Company of the free allocation rights as a consequence of the Purchase Commitment.
4. Designate the company or companies that assume the functions of agent and/or financial adviser for the Capital Increase and subscribe, for this purpose, as many contracts and documents as necessary.
5. Establish the duration of the negotiation period for the free allocation rights.
6. Establish the period during which the Purchase Commitment will be in effect.
7. Responsibility for the Purchase Commitment, paying the corresponding amounts to those who accept this commitment.
8. Declare the Capital Increase closed and executed and establishing, for these purposes, the number of New Shares effectively allocated and, therefore, the amount by which the Company's capital must be increased in accordance with the rules established by this

General Shareholders' Meeting, as well as declaring, where appropriate, the incomplete subscription of the Capital Increase.

9. Redraft the article of the Company Bylaws that regulates the share capital in order to reflect the new capital and the number of outstanding shares resulting from the execution of the Capital Increase.
10. Waive, when applicable, the free allocation rights that the Company holds following the conclusion of the corresponding trading period as a consequence of the Purchase Commitment and, therefore, the New Shares corresponding to these rights.
11. Waive, if applicable, free allocation rights for the subscription of New Shares for the sole purpose of facilitating a whole number of New Shares, rather than a fraction.
12. To undertake all the procedures necessary for the New Shares to be included in the accounting records of Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A. Unipersonal (IBERCLEAR) and admitted for trading on the Stock Markets of Bilbao, Madrid, Barcelona and Valencia, via the Spanish Stock Market Interconnection System (Continuous Market).
13. Undertake any actions necessary or appropriate to implement and formalise the Capital Increase before any public, private, Spanish or foreign entities and organisations, including declarations, supplementary actions or the correction of defects or omissions that might prevent or hinder the full effectiveness of the resolutions.

The Board of Directors is expressly authorised to delegate, under the terms of Article 249.2 of the Corporate Companies Act, the powers to which this agreement refers.

FIFTH Delegation of powers to the Board of Directors, with express power of substitution, for the entry into, construction, correction and/or execution of the resolutions adopted by the General Shareholders' Meeting.

To delegate and, when appropriate, to expressly authorise the Board of Directors, which may delegate jointly and severally to the Chair of the Board, the non-executive Secretary, and to the Directors, in order that any of the same may, jointly and severally, formalise, interpret, develop, implement, perform, rectify, and notarise the resolutions adopted at this General Shareholders' Meeting, and in particular to proceed to the presentation in the Companies Registry, for their deposit, of the certification of the resolutions approving the financial statements and the allocation of profit, attaching all legally-required documents, as well as granting such public and/or private documents necessary to obtain the corresponding inscription in the Companies Register of the resolutions adopted, including applications for partial registration, with powers to correct or rectify, as applicable, in accordance with the qualification of the Registrar.

And for the applicable legal purposes, the Company's Board of Directors formulates this Proposal of Agreements, in Sant Joan Despi (Barcelona), on 18 March 2021.

The Chair

REIG JOFRE INVESTMENTS, S.L.

Ms Isabel Reig López

The non-executive Secretary

Mr Adolf Rousaud Viñas